| Ilya Shneyderman, | |
|
953 49th St, Brooklyn, NY 11219-2923 | |
| (718) 510-2557 | |
| (718) 283-6621 |
| Full Name | Ilya Shneyderman |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 33 Years |
| Location | 953 49th St, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265428528 | NPI | - | NPPES |
| 02150714 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | ME81790 (Florida) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 214315 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Millennium Dialysis | Brooklyn, NY | Dialysis facility |
| Maimonides Medical Center | Brooklyn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maimonides Medical Center Maimonides Division Of Renal Medic | 0840254439 | 5 |
| Maimonides Faculty Practice Plan | 7012808348 | 195 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center.
Ceram, the independent materials technology company, has recently helped Greatbatch Medical, providers of critical technologies used in medical devices, to gain FDA acceptance of its hydroxyapatite coating master file by providing all the necessary testing on the coating for a 510(k) implant submission.
University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.
› Verified 6 days ago
| Entity Name | Maimonides Faculty Practice Plan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053344846 PECOS PAC ID: 7012808348 Enrollment ID: O20040324000597 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center.
Ceram, the independent materials technology company, has recently helped Greatbatch Medical, providers of critical technologies used in medical devices, to gain FDA acceptance of its hydroxyapatite coating master file by providing all the necessary testing on the coating for a 510(k) implant submission.
University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.
› Verified 6 days ago
| Entity Name | Maimonides Medical Center Maimonides Division Of Renal Medic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679676563 PECOS PAC ID: 0840254439 Enrollment ID: O20041113000264 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center.
Ceram, the independent materials technology company, has recently helped Greatbatch Medical, providers of critical technologies used in medical devices, to gain FDA acceptance of its hydroxyapatite coating master file by providing all the necessary testing on the coating for a 510(k) implant submission.
University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ilya Shneyderman, 953 49th St, Department Of Nephrology Room #611, Brooklyn, NY 11219-2923 Ph: (718) 510-2557 | Ilya Shneyderman, 953 49th St, Brooklyn, NY 11219-2923 Ph: (718) 510-2557 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center.
Ceram, the independent materials technology company, has recently helped Greatbatch Medical, providers of critical technologies used in medical devices, to gain FDA acceptance of its hydroxyapatite coating master file by providing all the necessary testing on the coating for a 510(k) implant submission.
University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.
› Verified 6 days ago
Dr. Alexander Usorov, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Nephrology Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Nephrology Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Nephrology Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |